^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecentriq (atezolizumab)

    i
    Other names: MPDL3280A, RG7446, RO5541267, MPDL-3280A, RG-7446, RO 5541267, RO 554-1267, RG7446-42, RO-5541267, MPDL 3280A, RG 7446, RG744642, RG 744642, RG-744642, RO-5541267 IV, MPDL 3280A IV
    Company:
    Roche
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    22h
    AMBITION: A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P3, N=281, Completed, Japanese Foundation for Cancer Research | Trial completion date: Sep 2025 --> Mar 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HR positive • HER-2 negative
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel
    23h
    ML41701: A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. (clinicaltrials.gov)
    P2, N=22, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    24h
    Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis (clinicaltrials.gov)
    P2, N=6, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Nov 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Tecentriq (atezolizumab)
    1d
    BEATcc: Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (clinicaltrials.gov)
    P3, N=410, Completed, Grupo Español de Investigación en Cáncer de Ovario | Active, not recruiting --> Completed
    Trial completion
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • paclitaxel
    1d
    Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Huashan Hospital
    New P1 trial
    |
    Tecentriq (atezolizumab) • YSCH-01
    1d
    Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=550, Recruiting, Pfizer | N=182 --> 550
    Enrollment change • Trial initiation date
    |
    Tecentriq (atezolizumab)
    2d
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    2d
    Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov)
    P1/2, N=85, Recruiting, Mayo Clinic | Trial completion date: Feb 2028 --> Aug 2029 | Trial primary completion date: Aug 2027 --> Aug 2029
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    3d
    Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update. (PubMed, J Clin Oncol)
    Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • ASPSCR1 (ASPSCR1 Tether For SLC2A4)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    4d
    Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis. (PubMed, Target Oncol)
    Avelumab has the highest risk of IRRs followed by atezolizumab and dual ICIs. This comparative study provides insight into the incidence of IRRs with ICI regimens. These results are useful in assessing which systemic therapies are responsible for IRRs, particularly when ICIs are combined with other agents.
    Retrospective data • Review • Journal • Checkpoint inhibition
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Bavencio (avelumab) • relatlimab (BMS-986016)
    4d
    A Curious Case of HLH: A Case Report of Hemophagocytic Lymphohistiocytosis Secondary to Atezolizumab. (PubMed, Case Rep Hematol)
    A 65-year-old man presented to the hospital with multiorgan failure in the setting of recently being started on atezolizumab for his small cell lung cancer. This presentation of HLH was also difficult due to the lack of fever, hepatomegaly, and cytopenias commonly seen as the presenting symptoms in HLH. Prompt initiation of treatment for HLH is critical, and due to this challenging presentation, this patient did not receive steroids and tocilizumab until Days 4 and 5, respectively.
    Journal
    |
    IL2 (Interleukin 2)
    |
    Tecentriq (atezolizumab) • Actemra IV (tocilizumab)
    5d
    CHANCE2202: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC (clinicaltrials.gov)
    P=N/A, N=941, Completed, Zhongda Hospital | Recruiting --> Completed | N=220 --> 941 | Trial completion date: Sep 2023 --> Sep 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Zepsun (donafenib)